Healthcare and life sciences investment firm Santé Ventures reported on Wednesday that it has raised USD250m in its oversubscribed healthcare and life science fund, Fund III, exceeding the target by 25%.
Fund III secured capital commitments from over 30 limited partners, including new investor Pennsylvania Public School Employees' Retirement System (PSERS).
Upon close, Fund III will be utilised to build a portfolio of 20-25 investments. To date, Fund III has committed 6.5% of capital into several investments, including Cryosa for the treatment of sleep apnea, DyaMX for the treatment of Type II Diabetes, as well as Geneos Therapeutics, a neoantigen-based personalized cancer therapy.
Fund III is almost twice as large as its predecessor. Investors in previous funds accounted for approximately one-half of the total capital.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults